+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Subcutaneous Immunoglobulin Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Subcutaneous Immunoglobulin Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Sale

Subcutaneous Immunoglobulin Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5889355
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Subcutaneous Immunoglobulin Market grew from USD 10.46 billion in 2024 to USD 11.63 billion in 2025. It is expected to continue growing at a CAGR of 10.91%, reaching USD 19.48 billion by 2030.

The subcutaneous immunoglobulin market has emerged as a pivotal segment within immunotherapy, offering patients more convenient and flexible treatment options for a range of immune-mediated conditions. Unlike traditional intravenous immunoglobulin therapy, subcutaneous administration enables self-administration at home, reduces infusion-related adverse events, and often improves quality of life through shorter administration times and fewer clinic visits. As health systems worldwide strive to optimize patient-centric care amid rising chronic disease burdens, the importance of subcutaneous formulations continues to gain traction among clinicians, payers, and policymakers.

In this executive summary, key developments, market drivers, and strategic considerations are distilled to guide decision-makers. The analysis encompasses regulatory milestones, reimbursement landscapes, and evolving therapeutic paradigms. By synthesizing macro- and micro-level insights, this overview establishes a foundation for stakeholders seeking to navigate competitive pressures, policy changes, and emerging patient needs. This introduction sets the stage for a deeper exploration of transformative shifts, tariff impacts, segmentation nuances, regional dynamics, competitive positioning, and actionable recommendations.

Transformative Shifts Redefining Treatment Paradigms

The landscape of subcutaneous immunoglobulin therapy is undergoing a profound transformation driven by technological innovation, regulatory momentum, and shifting patient expectations. Over recent years, novel delivery devices-such as wearable pumps and high-concentration formulations-have enabled more efficient dosing and enhanced flexibility. Concurrently, regulatory agencies in key markets have expanded indications, facilitating broader access for conditions ranging from primary immunodeficiency diseases to multifocal motor neuropathy.

Furthermore, the rise of patient support programs and telehealth integration has empowered individuals to manage treatment pathways more autonomously. As value-based care frameworks take hold, payers and health systems are increasingly evaluating therapies on total-cost-of-care metrics, positioning subcutaneous immunoglobulin as a compelling alternative to intravenous administration. These developments converge to redefine treatment paradigms, elevating patient experience while challenging manufacturers and providers to innovate across channels. Transitioning from facility-based infusions toward decentralized care models, the market is set to embrace new efficiencies, foster competitive differentiation, and reshape long-term strategy.

Assessing the 2025 US Tariff Impact on Subcutaneous Immunoglobulin

In 2025, newly imposed tariffs on imported immunoglobulin products in the United States have introduced supply chain complexities and cost pressures across the subcutaneous immunoglobulin market. Manufacturers sourcing active ingredients from global suppliers face elevated input costs, leading some to negotiate alternative agreements or localize production. Payers and providers, in turn, are evaluating contract terms to mitigate margin erosion, while a subset has explored tiered pricing arrangements or introduced co-pay assistance to safeguard patient access.

These tariff-related adjustments have prompted greater emphasis on sourcing diversification, with strategic alliances forming between domestic producers and international players. Additionally, manufacturers are exploring formulation efficiencies to offset cost burdens, such as higher-concentration solutions that reduce shipment volumes and administration frequency. As a result, supply reliability and affordability have become central considerations for stakeholders. Looking ahead, ongoing dialogue among industry, regulators, and payers will be crucial to balance fiscal objectives with uninterrupted patient care.

Key Segmentation Insights Driving Market Dynamics

A detailed segmentation analysis illuminates drivers behind market adoption and revenue streams. Based on application, the subcutaneous immunoglobulin market spans autoimmune diseases, neurological disorders, primary immunodeficiency diseases, and secondary immunodeficiency diseases. Within autoimmune diseases, Kawasaki disease and myasthenia gravis represent high-severity niches where targeted immunomodulation is critical. In neurological disorders, chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy drive demand for steady-state immunoglobulin levels to manage symptom flares. Primary immunodeficiencies such as agammaglobulinemia, chronic immune thrombocytopenic purpura, hypogammaglobulinemia, and specific antibody deficiency underscore the necessity of lifelong prophylactic treatment. Secondary immunodeficiencies, including hematological malignancies, HIV/AIDS, and organ transplantation, further underscore the therapy’s role in bolstering compromised immune systems.

Turning to product type, the market differentiates between human normal immunoglobulin and specific immunoglobulin. Human normal immunoglobulin options are available in both liquid and lyophilized presentations, catering to diverse storage and administration preferences. Specific immunoglobulin products target particular pathogens or clinical situations, offering precision therapy. Understanding these segments supports targeted marketing, formulary positioning, and resource allocation, enabling stakeholders to tailor clinical development, distribution strategies, and patient support initiatives to evolving needs.

Critical Regional Variations Shaping Market Opportunities

Geographic trends reveal distinct growth patterns and strategic priorities. In the Americas, established healthcare infrastructures, mature reimbursement frameworks, and high physician familiarity underpin robust adoption of subcutaneous immunoglobulin. Market participants focus on expanding self-administration training and home infusion services to optimize patient throughput and reduce hospitalization rates.

In the Europe, Middle East & Africa region, regulatory harmonization across the EU has accelerated approval pathways, while emerging markets within the Middle East and Africa present untapped demand despite logistical challenges. Key initiatives include capacity building for local infusion centers and forging public-private partnerships to enhance access.

Across Asia-Pacific, rapid population aging, rising chronic disease prevalence, and strengthening healthcare investments drive demand. Markets such as Japan, South Korea, and Australia showcase advanced reimbursement schemes, whereas opportunities in Southeast Asia and India hinge on affordability and supply chain enhancements. Tailoring distribution networks, pricing strategies, and educational outreach to regional nuances will be pivotal for growth.

Competitive Landscape: Leading Players Spotlight

The competitive landscape is defined by a blend of established pharmaceutical giants and specialized biotherapies innovators. Biotest AG by Grifols S.A. leverages legacy plasma expertise to advance high-concentration formulations, while CSL Behring continues to expand its patient support infrastructure globally. Kedrion Biopharma Inc. emphasizes strategic partnerships and emerging market entry, and Octapharma AG invests in novel delivery technologies to enhance administration convenience.

Takeda Pharmaceutical Company Limited integrates R&D capabilities with robust commercial networks, targeting broad therapeutic indications. The Bio Products Laboratory focuses on tailored immunoglobulin variants and manufacturing resilience. These leading players compete on multiple fronts-including formulation innovation, manufacturing scale, distribution reach, and patient engagement programs-to capture market share and reinforce clinical value propositions. Monitoring portfolio expansions, licensing agreements, and strategic alliances will be essential for benchmarking competitive performance.

Actionable Recommendations for Industry Leaders

To navigate the evolving subcutaneous immunoglobulin market, industry leaders should consider a multi-pronged strategic approach. First, optimizing portfolio breadth by balancing human normal and specific immunoglobulin offerings can capture diverse clinical needs. Second, expanding patient support programs-such as digital training modules and remote monitoring-enhances adherence and outcomes, strengthening payer value narratives.

Third, forging strategic alliances with local manufacturers or contract development organizations can mitigate tariff impacts and secure supply continuity. Fourth, investing in advanced delivery technologies, including wearable infusion devices and high-concentration formulations, differentiates brands and supports premium pricing. Fifth, tailoring regional strategies to address reimbursement complexities and distribution challenges ensures that resource allocation aligns with market potential.

Finally, fostering collaborative dialogues with payers and regulatory bodies to shape favorable policy environments will underpin sustainable growth. By integrating these recommendations into strategic planning, organizations can drive operational excellence, reinforce competitive positioning, and ultimately deliver enhanced patient care.

Conclusion: Consolidating Insights for Strategic Advantage

The subcutaneous immunoglobulin market sits at the intersection of clinical innovation, patient-centric care, and evolving economic pressures. By synthesizing insights from transformative treatment shifts, tariff-induced cost dynamics, segmentation analysis, and regional nuances, stakeholders can form a cohesive view of emerging opportunities and challenges.

Manufacturers must balance innovation with affordability, leveraging advanced formulations and delivery systems while maintaining accessible pricing models. Providers and payers, in turn, should collaborate to streamline administration protocols and optimize patient support pathways. Through concerted efforts across the value chain, the market is well positioned to sustain momentum, deepen therapeutic impact, and enhance quality of life for patients with immunological disorders.

Market Segmentation & Coverage

This research report categorizes the Subcutaneous Immunoglobulin Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Autoimmune Diseases
    • Kawasaki Disease
    • Myasthenia Gravis
  • Neurological Disorders
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Multifocal Motor Neuropathy
  • Primary Immunodeficiency Diseases
    • Agammaglobulinemia
    • Chronic Immune Thrombocytopenic Purpura
    • Hypogammaglobulinemia
    • Specific Antibody Deficiency
  • Secondary Immunodeficiency Diseases
    • Hematological Malignancies
    • HIV/AIDS
    • Organ Transplantation
  • Human Normal Immunoglobulin
    • Liquid
    • Lyophilized
  • Specific Immunoglobulin

This research report categorizes the Subcutaneous Immunoglobulin Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Subcutaneous Immunoglobulin Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Biotest AG by Grifols S.A.
  • CSL Behring
  • Kedrion Biopharma Inc.
  • Octapharma AG
  • Takeda Pharmaceutical Company Limited
  • The Bio Products Laboratory

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Subcutaneous Immunoglobulin Market, by Application
8.1. Introduction
8.2. Autoimmune Diseases
8.2.1. Kawasaki Disease
8.2.2. Myasthenia Gravis
8.3. Neurological Disorders
8.3.1. Chronic Inflammatory Demyelinating Polyneuropathy
8.3.2. Multifocal Motor Neuropathy
8.4. Primary Immunodeficiency Diseases
8.4.1. Agammaglobulinemia
8.4.2. Chronic Immune Thrombocytopenic Purpura
8.4.3. Hypogammaglobulinemia
8.4.4. Specific Antibody Deficiency
8.5. Secondary Immunodeficiency Diseases
8.5.1. Hematological Malignancies
8.5.2. HIV/AIDS
8.5.3. Organ Transplantation
9. Subcutaneous Immunoglobulin Market, by Product Type
9.1. Introduction
9.2. Human Normal Immunoglobulin
9.2.1. Liquid
9.2.2. Lyophilized
9.3. Specific Immunoglobulin
10. Americas Subcutaneous Immunoglobulin Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Subcutaneous Immunoglobulin Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Subcutaneous Immunoglobulin Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2024
13.2. FPNV Positioning Matrix, 2024
13.3. Competitive Analysis
13.3.1. Biotest AG by Grifols S.A.
13.3.2. CSL Behring
13.3.3. Kedrion Biopharma Inc.
13.3.4. Octapharma AG
13.3.5. Takeda Pharmaceutical Company Limited
13.3.6. The Bio Products Laboratory
14. ResearchAI
15. ResearchStatistics
16. ResearchContacts
17. ResearchArticles
18. Appendix
List of Figures
FIGURE 1. SUBCUTANEOUS IMMUNOGLOBULIN MARKET MULTI-CURRENCY
FIGURE 2. SUBCUTANEOUS IMMUNOGLOBULIN MARKET MULTI-LANGUAGE
FIGURE 3. SUBCUTANEOUS IMMUNOGLOBULIN MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 12. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 14. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 20. SUBCUTANEOUS IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY KAWASAKI DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY MYASTHENIA GRAVIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AGAMMAGLOBULINEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HYPOGAMMAGLOBULINEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIFIC ANTIBODY DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HIV/AIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY ORGAN TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIFIC IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 54. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 56. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 57. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 58. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 59. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 60. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 61. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 63. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 64. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 65. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 66. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 67. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 80. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 81. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 82. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 83. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 85. AUSTRALIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 86. AUSTRALIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 87. AUSTRALIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 88. AUSTRALIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 89. AUSTRALIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 90. AUSTRALIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 91. CHINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. CHINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 93. CHINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 94. CHINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 95. CHINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 96. CHINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 97. CHINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 98. INDIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. INDIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 100. INDIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 101. INDIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 102. INDIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 103. INDIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 104. INDIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 105. INDONESIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 106. INDONESIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 107. INDONESIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 108. INDONESIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 109. INDONESIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 110. INDONESIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 111. INDONESIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 112. JAPAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 113. JAPAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 114. JAPAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 115. JAPAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 116. JAPAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 117. JAPAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 118. JAPAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 119. MALAYSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. MALAYSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 121. MALAYSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 122. MALAYSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 123. MALAYSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 124. MALAYSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 125. MALAYSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 126. PHILIPPINES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. PHILIPPINES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 128. PHILIPPINES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 129. PHILIPPINES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 130. PHILIPPINES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 131. PHILIPPINES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 132. PHILIPPINES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 133. SINGAPORE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. SINGAPORE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 135. SINGAPORE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 136. SINGAPORE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 137. SINGAPORE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 138. SINGAPORE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 139. SINGAPORE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 140. SOUTH KOREA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. SOUTH KOREA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 142. SOUTH KOREA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 143. SOUTH KOREA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 144. SOUTH KOREA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 145. SOUTH KOREA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 146. SOUTH KOREA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 147. TAIWAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. TAIWAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 149. TAIWAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 150. TAIWAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 151. TAIWAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 152. TAIWAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 153. TAIWAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 154. THAILAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 155. THAILAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 156. THAILAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 157. THAILAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 158. THAILAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 159. THAILAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 160. THAILAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 161. VIETNAM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 162. VIETNAM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 163. VIETNAM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 164. VIETNAM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 165. VIETNAM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 166. VIETNAM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 167. VIETNAM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 176. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 177. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 178. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 179. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 180. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 181. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 182. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 183. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 184. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 185. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 186. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 187. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 188. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 189. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 190. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 191. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 192. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 193. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 194. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 195. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 196. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 197. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 198. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 199. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 200. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 201. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 202. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 203. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 204. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 205. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 206. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 207. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 208. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 209. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 210. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 212. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 213. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 214. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 215. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 216. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 217. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 218. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 219. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 220. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 221. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 222. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 223. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 224. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 230. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 231. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 232. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 239. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 240. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 241. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 242. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 243. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 244. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 245. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 246. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 247. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 248. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 249. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 250. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 251. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 252. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 253. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 255. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 256. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 257. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 258. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 259. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 260. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 261. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 262. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 264. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 265. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 266. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 268. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 270. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 272. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 274. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 276. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 278. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 280. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 281. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 282. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 283. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 284. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 285. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 286. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 287. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HUMAN NORMAL IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 288. SWEDEN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 289. SWEDEN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 290. SWEDEN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 291. SWEDEN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2018-2030 (USD MILLION)
TABLE 292. SWEDEN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IM

Companies Mentioned

  • Biotest AG by Grifols S.A.
  • CSL Behring
  • Kedrion Biopharma Inc.
  • Octapharma AG
  • Takeda Pharmaceutical Company Limited
  • The Bio Products Laboratory

Methodology

Loading
LOADING...

Related Topics

Related Reports

Subcutaneous Immunoglobulin - Global Strategic Business Report - Product Image

Subcutaneous Immunoglobulin - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Subcutaneous Immunoglobulin (SCIG) Market Report 2025 - Product Image

Subcutaneous Immunoglobulin (SCIG) Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Intravenous Immunoglobulin Market by Indication, Form, End-User - Global Forecast 2025-2030 - Product Image

Intravenous Immunoglobulin Market by Indication, Form, End-User - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Immunoglobulins Market Report 2025 - Product Image

Immunoglobulins Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Immunoglobulin Market Report by Product, Mode of Delivery, and Region 2024-2032 - Product Image

Immunoglobulin Market Report by Product, Mode of Delivery, and Region 2024-2032

  • Report
  • 140 Pages
  • Global
From

About the Subcutaneous Immunoglobulin Market

The Subcutaneous Immunoglobulin (SCIg) market is a segment of the Immune Disorders Drugs market. SCIg is a form of immunoglobulin therapy used to treat a variety of immune-mediated diseases, such as primary immunodeficiencies, autoimmune diseases, and chronic inflammatory diseases. SCIg is administered through subcutaneous injections, which are less painful and more convenient than intravenous infusions. SCIg is also more cost-effective than intravenous immunoglobulin (IVIg). SCIg is a rapidly growing market, driven by the increasing prevalence of immune-mediated diseases and the growing demand for more convenient and cost-effective treatments. The market is expected to continue to grow in the coming years, as more patients are diagnosed with immune-mediated diseases and as new treatments become available. Some of the major players in the SCIg market include CSL Behring, Grifols, Kedrion, Octapharma, and Shire. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.